The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides, comprising: a) acid hydrolysis; b) a first ultrafiltration/diafiltration-(UFDF-1); b) carbon filtration; c) chromatography; and d) a second ultrafiltration/diafiltration-(UFDF-2).

The present disclosure discloses a method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide, and belongs to the field of carbohydrate chemistry. The present disclosure takes glucose as a glycosyl donor to obtain a target β-glucosidic bond, then successfully synthesizes a disaccharide building block through a method of redox of a glucose C-2 site, and then takes the disaccharide building block as a repeat unit to synthesize a target oligosaccharide structure such as a derivative [.fwdarw.3)-α-D-Manp-(1.fwdarw.4)-β-D-Rhap-(1.fwdarw.].sub.5-Linker of gram-positive bacteria cell wall capsular polysaccharide. A reduction end of decose is linked with a linker to be linked with a protein to make glycoconjugates for immunological studies. The method provided by the present disclosure is simple, time-saving, labor-saving and low-cost, and the resultant derivatives of the gram-positive bacteria surface capsular polysaccharide may be used for development and preparation of medicine related to autism.

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) .fwdarw.4)-β-D-Glcp-(1.fwdarw.4)-[Gro-(2.fwdarw.P.fwdarw.3)]-β-D-Galp-(1.fwdarw.4)-β-L-Rhap-(1.fwdarw.. Also provided are conjugates comprising a .fwdarw.4)-β-D-Glcp-(1.fwdarw.4)-[Gro-(2.fwdarw.P.fwdarw.3)]-β-D-Galp-(1.fwdarw.4)-β-L-Rhap-(1.fwdarw., immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

Disclosed herein is an ingestible composition comprising a sphingan and its use as a prebiotic.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

The present disclosure provides an aggregation-induced emission polymer, a preparation method and application thereof. The aggregation-induced emission polymer provided in the present disclosure has a structure represented by formula I. The aggregation-induced emission polymer provided by the present disclosure has excellent fluorescence stability and biocompatibility; Because there are many benzene rings in the aggregation-induced emission polymer, the fat-solubility of the aggregation-induced emission polymer is increased, thereby changing the problem that cellulose is insoluble and difficult to be processed and modified. In the present disclosure, the aggregation-induced emission small molecule monomer is placed in a basal medium, and the bacterial seed solution is inoculated and then cultured to obtain the aggregation-induced emission polymer. The preparation method provided by the present disclosure has the characteristics of safety, environmental protection and simplicity, solves the shortcomings of complex and cumbersome synthesis process, and is beneficial to the large-scale production of AIE polymers.

A purified composition of steviol glycoside molecules is described. The composition imparts desirable taste, flavor and flavor modifying properties to food, beverages, and other consumable products.